At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
Hybrid APCdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hybrid APC Assisted EMR for Large Colon Polyps to Reduce Local Recurrence : A Prospective Data Collection Study
In Brief
A clinical study evaluating Hybrid APC for Colon Polyp and 2 related conditions. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study to evaluate and examine whether use of Hybrid Argon Plasma Coagulation (APC) as an adjunct to endoscopic mucosal resection (EMR) will reduce the risk of residual or recurrent neoplasia at 6 months. Hybrid APC is an existing FDA approved device used to assist with ablation of abnormal tissue anywhere in the GI tract.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Polyp, Colon Adenoma, Colon Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartSep 2018
Primary CompletionOct 2020
TodayJul 2026
First PostedJan 4, 2018
Enrollment StartSep 28, 2018
Primary CompletionOct 27, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.5 years ago
Interventions
Hybrid APCdevice
Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.